Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone‐induced atopic dermatitis model

Even with the widespread clinical use of cannabinoid receptor (CBR) stimulating compounds, such as palmitoylethanolamine, the role of CBR agonists on inflammatory skin diseases is not yet fully understood. This study was performed to investigate the effects of CBR agonists on skin inflammation, using acute and chronic inflammation animal models.

[1]  B. Lutz,et al.  Cannabinoid 1 Receptors in Keratinocytes Modulate Proinflammatory Chemokine Secretion and Attenuate Contact Allergic Inflammation , 2013, The Journal of Immunology.

[2]  P. Elias,et al.  Cannabinoid receptors 1 and 2 oppositely regulate epidermal permeability barrier status and differentiation , 2012, Experimental dermatology.

[3]  R. Paus,et al.  Endocannabinoids limit excessive mast cell maturation and activation in human skin. , 2012, The Journal of allergy and clinical immunology.

[4]  D. Simon,et al.  Atopic dermatitis: from new pathogenic insights toward a barrier-restoring and anti-inflammatory therapy , 2011, Current opinion in pediatrics.

[5]  M. Boguniewicz,et al.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation , 2011, Immunological reviews.

[6]  R. Paus,et al.  Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. , 2011, The Journal of investigative dermatology.

[7]  S. Petrosino,et al.  N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. , 2010, Biochimie.

[8]  R. Mechoulam,et al.  Novel natural and synthetic ligands of the endocannabinoid system. , 2010, Current medicinal chemistry.

[9]  T. Bisogno,et al.  Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. , 2010, Bioorganic & medicinal chemistry letters.

[10]  R. Paus,et al.  The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. , 2009, Trends in pharmacological sciences.

[11]  P. Ong.  Emerging drugs for atopic dermatitis , 2009, Expert opinion on emerging drugs.

[12]  B. Costa,et al.  The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors , 2008, PAIN.

[13]  P. Elias,et al.  Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. , 2008, The Journal of allergy and clinical immunology.

[14]  E. D. del Giudice,et al.  A Saturated N‐Acylethanolamine Other than N‐Palmitoyl Ethanolamine with Anti‐inflammatory Properties: a Neglected Story… , 2008, Journal of neuroendocrinology.

[15]  M. Maccarrone,et al.  Anandamide Regulates Keratinocyte Differentiation by Inducing DNA Methylation in a CB1 Receptor-dependent Manner* , 2008, Journal of Biological Chemistry.

[16]  J. Ring,et al.  Adjuvant treatment of atopic eczema: assessment of an emollient containing N‐palmitoylethanolamine (ATOPA study) , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[18]  E. Williamson,et al.  Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. , 2007, Journal of dermatological science.

[19]  T. Sugiura,et al.  Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in Oxazolone-Induced Contact Dermatitis in Mice1 , 2006, The Journal of Immunology.

[20]  R. Paus,et al.  Frontiers in pruritus research: scratching the brain for more effective itch therapy. , 2006, The Journal of clinical investigation.

[21]  S. Nikas,et al.  CB1 cannabinoid receptor ligands. , 2005, Mini reviews in medicinal chemistry.

[22]  P. Elias,et al.  Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. , 2005, The Journal of investigative dermatology.

[23]  E. Choi,et al.  The characterization of molecular organization of multilamellar emulsions containing pseudoceramide and type III synthetic ceramide. , 2003, The Journal of investigative dermatology.

[24]  A. Finazzi-Agro’,et al.  The Endocannabinoid System in Human Keratinocytes , 2003, Journal of Biological Chemistry.

[25]  S. Bell,et al.  Endogenous cannabinoids: metabolism and their role in reproduction. , 2002, Life sciences.

[26]  P. Elias,et al.  Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. , 2008, The Journal of investigative dermatology.

[27]  Cristina Blázquez,et al.  Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. , 2003, The Journal of clinical investigation.

[28]  Myungjin Lee,et al.  RESEARCH PAPERS : The Synthesis of New Pseudoceramides using Alkylketene Dimer and Their Physical Properties , 1999 .

[29]  이종기,et al.  The Synthesis of New Pseudoceramides using Alkylketene Dimer and Their Physical Properties , 1999 .

[30]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.